 - The participant may have no more than 2 prior lines of systemic therapies neoadjuvant and adjuvant therapies will not be considered as a prior line of therapy for advanced or metastatic disease and is suitable to receive gemcitabine and docetaxel therapy. All previous therapies must have completed 3 weeks 21 days prior to first dose of study drug. 